US Patent

US10959982 — Duloxetine sprinkles

Formulation · Assigned to Sun Pharmaceutical Industries Ltd · Expires 2037-04-13 · 11y remaining

Vulnerability score 42/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a multiparticulate sprinkle dosage form of duloxetine or a pharmaceutically acceptable salt thereof with higher acid resistance.

USPTO Abstract

The present invention relates in part a to multiparticulate sprinkle dosage form comprising duloxetine or a pharmaceutically acceptable salt thereof, having higher acid resistance as compared to commercially available delayed release formulations. It further relates to various methods of administering the said multiparticulate sprinkle dosage forms.

Drugs covered by this patent

Patent Metadata

Patent number
US10959982
Jurisdiction
US
Classification
Formulation
Expires
2037-04-13
Drug substance claim
No
Drug product claim
Yes
Assignee
Sun Pharmaceutical Industries Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.